Pharmaceuticals

Yunnan Baiyao

Yunnan Baiyao released FY2026 Q1 earnings on April 29 During-Market (BJT), actual revenue CNY 11.6 B (forecast CNY 11.04 B), actual EPS CNY 1.14 (forecast CNY 0.9224)

Yunnan Baiyao to Release FY2026 Q1 Earnings on April 30 During-Market (BJT), Forecast Revenue CNY 11.04 B, EPS CNY 0.8149

Yunnan Baiyao released FY2025 Q4 earnings on March 31 After-Market (BJT), actual revenue CNY 10.53 B (forecast CNY 10.53 B), actual EPS CNY 0.2108 (forecast CNY 0.2634)

Yunnan Baiyao released FY2025 earnings on March 31 After-Market (BJT), actual revenue CNY 41.19 B (forecast CNY 41.73 B), actual EPS CNY 2.89 (forecast CNY 2.9673)

Yunnan Baiyao to Release FY2025 Earnings on April 1 After-Market (BJT), Forecast Revenue CNY 41.73 B, EPS CNY 2.9673

Yunnan Baiyao released FY2025 9 Months Earnings on October 30 During-Market (BJT), actual revenue CNY 30.65 B, actual EPS CNY 2.6799

Yunnan Baiyao released FY2025 Q3 earnings on October 30 During-Market (BJT), actual revenue CNY 9.397 B (forecast CNY 10.14 B), actual EPS CNY 0.6407 (forecast CNY 0.7342)

Yunnan Baiyao to release FY2025 Q3 earnings on October 31 During-Market BJT, forecast revenue CNY 10.14 B, EPS CNY 0.7342

Yunnan Baiyao released FY2025 Q2 earnings on August 29 During-Market (BJT), actual revenue CNY 10.42 B (forecast CNY 10.09 B), actual EPS CNY 0.9592 (forecast CNY 0.9165)

Yunnan Baiyao released FY2025 Semi-Annual Earnings on August 29 During-Market (BJT), actual revenue CNY 21.26 B, actual EPS CNY 2.04

Yunnan Baiyao FY2025 Semi-Annual Earning Release on August 30, 2025 (BJT)

Domestic Brands Rise in Offline Toothpaste Market, Yunnan Baiyao Dominates

Yunnan Baiyao's ESG Rating Rises to A

Yunnan Baiyao's Chinese Medicinal Materials Traceability Query Passes Shanghai Data Exchange Listing Review

Yunnan Baiyao Reports Q1 2025 Revenue Growth

YNBY Obtains Exclusive Distribution Rights for Yunnan Baiyao in Overseas Markets

Yunbai International Obtains Exclusive Global Distribution Rights for Yunnan Baiyao Group Products

Yunnan Baiyao Subsidiary Zhenwu Technology Receives Approval for Clinical Trials of JZ-14 Capsules for Ulcerative Colitis

Yunnan Baiyao's Four Business Divisions Steadily Develop

Share Freeze of Yunnan Baiyao Holding Investment Co., Ltd.

512290

159929

600436

000538

03613

With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibited

Wallstreetcn

Guotai CSI Bio-medicine ETF

China Universal 800 Health Care ETF

ZZPZH

CR Sanjiu

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

TRAD CHI MED

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

TAIJI GROUP

TASLY

Penghua SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

DRTG

E Fund CSI HK Equities Medical and Health Integration ETF

BAIYUNSHAN PH

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

YILING PHARMACEUTICAL

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

JUMPCAN

Tianhong CNI BIOMEDICINE ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

TONG REN TANG

TONGRENTANGCM

GYBYS

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI 300 Health Care ETF

002614

688410

On November 4th, the National Health Commission issued the "Implementation Opinions on Promoting and Regulating the Development of 'Artificial Intelligence + Healthcare' Applications." Several A-share companies, such as SWS Medical, Yunnan Baiyao, and EASEPAL, have already laid out plans in the "Artificial Intelligence + Healthcare" field. The implementation opinions clarify the direction of industry support and key application areas, bringing new business expansion opportunities to related listed companies and aiding in performance growth

EASEPAL

SWS Medical

"Artificial Intelligence + Healthcare" welcomes new policies, multiple listed companies are expected to benefit

According to the Zhitong Finance APP, Yunnan Baiyao released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 30.654 billion yuan, a year-on-year increase of 2.47%. The net profit attributable to shareholders of the listed company was 4.777 billion yuan, a year-on-year increase of 10.41%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 4.55 billion yuan, a year-on-year increase of 6.68%. The basic earnings per share were 2.68 yuan

Zhitong

Yunnan Baiyao released its performance for the first three quarters, with a net profit attributable to the parent company of 4.777 billion yuan, an increase of 10.41%

Yunnan Baiyao announced that its revenue for the third quarter was 9.397 billion yuan, a year-on-year decrease of 0.66%; net profit was 1.144 billion yuan, a year-on-year increase of 0.55%. Revenue for the first three quarters was 30.654 billion yuan, a year-on-year increase of 2.47%; net profit was 4.777 billion yuan, a year-on-year increase of 10.41%

Yunnan Baiyao: Net profit in the third quarter was 1.144 billion yuan, a year-on-year increase of 0.55%

ZZPZH faces a turning point in the traditional Chinese medicine industry in 2025, with the third quarterly report showing a sharp decline in both revenue and net profit, down 11.9% and 20.7% respectively. The market value has dropped from 270 billion yuan in 2021 to 109.031 billion yuan, evaporating nearly 60%. A structural turning point is emerging in the overall industry, with traditional growth models gradually disappearing. ZZPZH needs to explore new growth methods to meet the challenges

- The traditional Chinese medicine industry is at a turning point in 2025, with nearly one-third of listed companies reporting revenue growth, but less than half achieving profit increases.  
- The recent financial report from Pianzaihuang revealed a significant decline in revenue and net profit, confirming the industry's struggles as reliance on price increases and unique products wanes.  
- As the market shifts, the industry must explore new growth strategies beyond price hikes, facing challenges such as rising raw material costs and changing consumer behavior.

The market value of the hundred billion is in jeopardy! After a 20% plunge in profits, how will "Chinese medicine Moutai" ZZPZH turn the tide?

YNBY International Limited has updated details on its connected transactions for the year ending December 31, 2024, including transaction amounts and annual caps with Yunnan Baiyao Group. The pricing policy is based on market conditions, allowing for profit margins. Ban Loong Holdings Limited (HK:0030) has a Hold rating with a price target of HK$0.50. The stock has shown a YTD price performance of 41.71% and a market cap of HK$1.9B.

Tip Ranks

YNBY International Limited Reveals Details on Connected Transactions

According to Yunnan Baiyao, recently, the sugar-free research project of the Xiangsha Pingwei granules, jointly undertaken by the Central Research Institute of Yunnan Baiyao Group and the Pharmaceutical Business Group, has received the supplementary application approval from the National Medical Products Administration

Yunnan Baiyao: Xiangsha Pingwei Granules have obtained the drug supplementary application approval